Cardiogenic Shock News and Research

RSS

Cardiogenic shock is based upon an inadequate circulation of blood due to primary failure of the ventricles of the heart to function effectively.

Trial finds benefits in using radial approach for primary angioplasty in heart attack patients

A study found several benefits in using the radial artery in the arm as the entry point for angioplasty or percutaneous coronary intervention (PCI) compared to the femoral artery in the leg. Results of the STEMI-RADIAL trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

29 Oct 2012

Simple-to-use risk score can identify low-risk STEMI patients for early discharge

A simple-to-use risk score can identify low-risk patients following a severe heart attack (STEMI) and may provide an opportunity to employ early discharge strategies to reduce length of hospital stay and save hospital costs without compromising the safety of the patient, based on a study presented by the Minneapolis Heart Institute Foundation on Oct. 23 at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) conference.

24 Oct 2012

Public reporting states have low angioplasty rates

US states in which public reporting of percutaneous coronary intervention rates by catheterization laboratories is required may have a reduced rate of the procedure in acute myocardial infarction patients, research suggests.

11 Oct 2012

Stenting outcomes worse for elderly women than men

Results from a cohort study published in Cardiology show that elderly women have a higher risk for complications and in-hospital mortality immediately after treatment with either drug-eluting stents or bare metal stents than elderly men.

4 Oct 2012

Acute Cardiac Care Congress to be held in Istanbul, Turkey

More than 400 scientific abstracts will be presented by international scientists, providing a great source of news stories for journalists.

10 Sep 2012

Study explores gender-related differences in patients hospitalized for acute heart failure

Women with acute heart failure have similar in-hospital mortality to men but are less treated in the real world, according to results from the global ALARM-HF registry presented today at the ESC Congress 2012. The findings were presented by Dr John T. Parissis from Greece.

27 Aug 2012

IABP does not improve blood pressure symptoms in patients with cardiogenic shock

A balloon pump inserted in the aorta is currently the most widely used support device in the treatment of cardiogenic shock and, since its introduction in 1968, has been used in several million people.

27 Aug 2012

Study confirms electrical storm as potent risk factor for death and impaired quality of life

Electrical storm (ES) is a potent risk factor for mortality and morbidity, according to research presented today at the ESC Congress 2012 by Dr Federico Guerra from Italy. Data was also presented on which patients are prone to developing ES and how effective current treatments are.

27 Aug 2012

VHVI now offers new minimally invasive, catheter-based approach to dissolve pulmonary embolism

The Vanderbilt Heart and Vascular Institute (VHVI) now offers a minimally invasive, catheter-based approach to dissolving pulmonary embolism, a potentially life-threatening blood clot that form elsewhere in the body and travels into the lungs.

17 Jul 2012

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced new clinical data presented in an oral presentation for ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use at the 17th Congress of the European Hematology Association (EHA).

19 Jun 2012

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.

18 May 2012

EKOS launches two landmark clinical studies on pulmonary embolism

EKOS Corporation today announced the launch of two more landmark clinical studies named SEATTLE I & II, intended to further establish the safety and efficacy of its unique, ultrasound-accelerated thrombolysis in treating patients with life-threatening pulmonary embolism.

3 May 2012

Abiomed's Impella cVAD device awarded CE Mark

Abiomed, Inc., a leading provider of break-through heart support technologies, today announced it has received CE Marking approval in the European Union to market the Impella cVAD device, a new percutaneous Impella® heart pump that provides peak flow of approximately 4 liters of blood per minute.

12 Apr 2012

Spectrum signs definitive agreement to acquire Allos

Spectrum Pharmaceuticals and Allos Therapeutics, Inc. today announced that they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of Allos for $1.82 per share in cash plus one Contingent Value Right.

6 Apr 2012

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Novartis announced today that following a priority review, the US Food and Drug Administration has approved an update to the Gleevec (imatinib mesylate) tablets label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial.

1 Feb 2012

ESC, SAGE to launch European Heart Journal: Acute Cardiovascular Care

SAGE and the European Society of Cardiology (ESC) have announced the launch of the European Heart Journal: Acute Cardiovascular Care.

19 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.

21 Nov 2011

Therapeutic hypothermia recommended for patients with preexisting cardiomyopathy

Cardiomyopathy is common among cardiac arrest survivors. The survival and neuroprotective benefits of therapeutic hypothermia is similar in patients with preexisting cardiomyopathy, compared with those patients without cardiomyopathy, according to a scientific poster being presented Nov. 14 at the American Heart Association (AHA) scientific sessions.

14 Nov 2011

Abiomed second quarter revenue increases 26% to $29.5 million

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2012 revenue of $29.5 million, up 26% compared to revenue of $23.4 million in the same period of fiscal 2011.

3 Nov 2011

Cardiogenic Shock News and Research

Further Reading

Trial finds benefits in using radial approach for primary angioplasty in heart attack patients

Simple-to-use risk score can identify low-risk STEMI patients for early discharge

Public reporting states have low angioplasty rates

Stenting outcomes worse for elderly women than men

Acute Cardiac Care Congress to be held in Istanbul, Turkey

Study explores gender-related differences in patients hospitalized for acute heart failure

IABP does not improve blood pressure symptoms in patients with cardiogenic shock

Study confirms electrical storm as potent risk factor for death and impaired quality of life

VHVI now offers new minimally invasive, catheter-based approach to dissolve pulmonary embolism

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

EKOS launches two landmark clinical studies on pulmonary embolism

Abiomed's Impella cVAD device awarded CE Mark

Spectrum signs definitive agreement to acquire Allos

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

ESC, SAGE to launch European Heart Journal: Acute Cardiovascular Care

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Therapeutic hypothermia recommended for patients with preexisting cardiomyopathy

Abiomed second quarter revenue increases 26% to $29.5 million

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News